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Rationale
Our main focus in the laboratory is to understanding
the mechanisms of how oral immunotherapy (OIT)
improves outcomes in patients. In this study, we aimed
to determine if OIT is specific only to the food allergens
administered in OIT or also to other offending allergens
(i.e. “bystander effect”). To accomplish our aim, we stu-
died T cell reactivity (i.e. proliferation assays) and T cell
specificity (i.e. tetramer assays with peanut peptides) in
both effector T cell (CD4+CD25neg) or Teff and regula-
tory T cell (CD4+CD25hiFoxp3+) or Treg subsets.
Methods
A phase I trial of oral immunotherapy for peanut allergy
was approved by the Stanford IRB and conducted
according to ICH guidelines. All subjects (n=24) had a
moderate to severe clinical reactions to peanut inges-
tion, peanut-specific IgE ≥ 15 kU/L, and a positive skin-
prick test. Subjects underwent an initial dose escalation
to a maximum dose prior to initiating daily home dos-
ing with q2wk dose. Blood samples were collected at
baseline and throughout the course of the treatment. T
cells were magnetically purified and tested for specificity
to peanut epitopes, other offending food allergens for
the patient, and a control antigen. Basophil reactivity
was also assessed using a whole blood assay. Clinical
assessments were performed using Bock’s criteria.
Results
Twenty-four subjects, ages 5 to 45, have received 3777
doses. Teff cell proliferation (using 3H thymidine assays)
was optimally suppressed by autologous Treg when
activation occurred using antigen presenting cells
(APCs) loaded with peanut, rather than loaded with
other offending food allergens (i.e. milk). Basophil reac-
tivity (as determined by CD203c) was downregulated
during the course of OIT to both peanut and other
offending allergens.
Conclusions
We report on our immune monitoring results to date at
Stanford Hospital and Clinics with a phase I peanut oral
immunotherapy study using published methods. With T
cell monitoring, we were able to show downregulation
of specific peanut-induced proliferation and that this
downregulation was mediated by Treg specific to peanut
epitopes.
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